N-(4-Oxocyclohexyl)acetamide

We are N-(4-Oxocyclohexyl)acetamide CAS:27514-08-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   N-(4-Oxocyclohexyl)acetamide
CAS.NO:  27514-08-5
Synonyms:
4-n-acetylamino cyclohexanone
4-Aminocyclohexanone,N-acetyl
N-acetyl-4-aminocyclohexanone
N-(4-Oxocyclohexyl)-acetamide
N-(4-Oxocyclohexyl)acetamid
4-Acetamidocyclohexanone
4-acetylamino-cyclohexanone
4-Acetamidocyclohexanon
4-N-Acetyl-amino-cyclohexanone

Molecular Formula: C8H13NO2
Molecular Weight:   155.19400

Physical and Chemical Properties:
Density: 1.071g / cm3
Boiling point: 359.086ºC at 760 mmHg
Melting point: 137 ° C
Flash point: 168.906ºC
Refractive index: 1.476

Specification:
Appearance: White powder
Purity:≥99.0%
Identification :IR
Loss on drying: 0.5% max.

 

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
N-(4-Oxocyclohexyl)acetamide is a metabolite of (trans-N-(4-nitroxycyclohexyl)acetamide (CAS 137213-91-3). N-(4-Oxocyclohexyl)acetamide has been used as a reactant in the preparation of 2-Pyrimidinecarbonitrile derivatives as falcipain inhibitors and antiparasitic agents. Intermediates of Pramipexole dihydrochloride CAS: 104632-25-9.

N-(4-Oxocyclohexyl)acetamide


Related News: This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine.598-72-1 This is called API. A small amount of the active ingredient has an effect, so only a tiny part of the active ingredient is contained in medicine.459-57-4 It has reserves in the direction of APIs and intermediates for lowering blood lipids, lowering blood sugar and anticoagulation.Glicilglicina CAS:556-50-3 As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.As part of the agreement, ICIG will enter into a 5-year supply contract to provide Genzyme with materials needed for the production of eliglustat tartrate, an investigational treatment for Gaucher disease Type 1 that is currently in Phase III clinical trials.

Related Products
Product Name
3-(5-bromo-2-phenylmethoxyphenyl)-3-phenyl-N,N-di(propan-2-yl)propan-1-amine View Details
1,1-Dimethoxy-2-(2-methoxyethoxy)ethane View Details
dodecamethylpentasiloxane View Details
cyclohexane-1,3-dione manufacturer 5-bromo-2-fluoro-3-methylpyridine manufacturer (3R,4S)-3-Hydroxy-4-phenylazetidin-2-one manufacturer 3-Bromoisonicotinic acid manufacturer D-Aspartic Acid manufacturer